Next Issue
Volume 11, May
Previous Issue
Volume 10, May
 
 
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.

Hematol. Rep., Volume 11, Issue 1 (February 2019) – 8 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Order results
Result details
Select all
Export citation of selected articles as:
5 pages, 364 KiB  
Article
The Use of Mean Platelet Volume for Distinguishing the Causes of Thrombocytopenia in Adult Patients
by Lalita Norrasethada, Wichan Khumpoo, Ekarat Rattarittamrong, Thanawat Rattanathammethee, Chatree Chai-Adisaksopha and Adisak Tantiworawit
Hematol. Rep. 2019, 11(1), 7732; https://doi.org/10.4081/hr.2019.7732 - 29 Mar 2019
Cited by 15 | Viewed by 850
Abstract
Establishment and analysis of mean platelet volume (MPV) may be helpful in the discrimination between underproduction or over-destruction of platelets as the causes of thrombocytopenia. The primary objective is to find the cut-off point of MPV for distinguishing causes of thrombocytopenia. The secondary [...] Read more.
Establishment and analysis of mean platelet volume (MPV) may be helpful in the discrimination between underproduction or over-destruction of platelets as the causes of thrombocytopenia. The primary objective is to find the cut-off point of MPV for distinguishing causes of thrombocytopenia. The secondary objective is to validate the cut-off value of the MPV by using bone marrow examination. Thrombocytopenic patients were enrolled in a training set and a receiving operating characteristics (ROC) curve was plotted to obtain the cut-off value of MPV. A validation set of patients was recruited to validate the cut-off value. The training set included 240 patients. Half with with underproductive (n = 120) and half with over-destructive thrombocytopenia (n = 120). The best cut-off value of MPV was 8.8 fL. The validation set included 119 patients in total, again in 2 groups, those with underproductive (n = 84) and those with overdestructive thrombocytopenia (n = 35). The sensitivity, specificity, PPV and NPV when MPV ≥ 8.8 fL indicating over-destructive thrombocytopenia were 77%, 89%, 89% and 77%, respectively. MPV is useful for differentiating the cause of thrombocytopenia. The value of MPV ≥ 8.8 fL has acceptable sensitivity and specificity for diagnosis of over-destructive thrombocytopenia. Full article
3 pages, 316 KiB  
Case Report
Relapsing Thrombotic Thrombocytopenic Purpura with Low ADAMTS13 Antigen Levels: An Indication for Splenectomy?
by Anna Maria Lombardi, Irene Di Pasquale, Maria Antonietta Businaro, Irene Cortella, Silvia Ferrari, Fabrizio Fabris and Fabrizio Vianello
Hematol. Rep. 2019, 11(1), 7904; https://doi.org/10.4081/hr.2019.7904 - 19 Mar 2019
Cited by 2 | Viewed by 393
Abstract
With more recent modalities of immunosuppression, splenectomy is now rarely considered in refractory/relapsed thrombotic thrombocytopenic purpura (TTP). However, the surgical approach had shown convincing evidences of high efficacy in the pre-rituximab era and therefore may still represent a lifesaving option in selected challenging [...] Read more.
With more recent modalities of immunosuppression, splenectomy is now rarely considered in refractory/relapsed thrombotic thrombocytopenic purpura (TTP). However, the surgical approach had shown convincing evidences of high efficacy in the pre-rituximab era and therefore may still represent a lifesaving option in selected challenging cases. To define the characteristics of subjects who may benefit from splenectomy may ease clinical decision making. In this paper we describe the clinical and laboratory data of 2 multiple relapsing TTP cases who successfully underwent splenectomy in the pre-rituximab era. Whereas high anti-ADAMTS13 antibody titre and low ADAMTS13 activity never correlated with remission and relapse, a drop in the ADAMTS13 antigen level was always associated with the acute phase, whereas levels consistently returned to normal following splenectomy, heralding long term remission. Splenectomy may therefore be considered in refractory TTP cases associated with increased ADAMTS13 antigen clearance, irrespective of persistence of inhibitory antibodies. Full article
4 pages, 374 KiB  
Case Report
MPL Y252H and MPL F126fs Mutations in Essential Thrombocythemia: Case Series and Review of Literature
by Ahmed G. Elsayed, Aeesha Ranavaya and Muhammad Omer Jamil
Hematol. Rep. 2019, 11(1), 7868; https://doi.org/10.4081/hr.2019.7868 - 12 Mar 2019
Cited by 6 | Viewed by 539
Abstract
Essential thrombocythemia (ET) is a clonal bone marrow disease, characterized by increased production of platelets along with other clinical and bone marrow findings. Most patients with ET will have a somatic mutation in one of the known gene locations of JAK2, CALR , [...] Read more.
Essential thrombocythemia (ET) is a clonal bone marrow disease, characterized by increased production of platelets along with other clinical and bone marrow findings. Most patients with ET will have a somatic mutation in one of the known gene locations of JAK2, CALR , or MPL that can upregulate the JAK-STAT pathway. MPL mutation is present in 5% of cases with the most common mutations being W515L and W515K. In this report we describe 2 cases of patients with clinical and laboratory picture of ET. One patient carried MPLY252H mutation which is previously unreported in the adult population but has been shown to be a gain-of-function mutation. The other patient carried MPL F126fs mutation which is not known to be of clinical importance and has not been previously reported. Full article
4 pages, 364 KiB  
Article
Studying Anemia of Chronic Disease and Iron Deficiency in Patients with Rheumatoid Arthritis by Iron Status and Circulating Hepcidin
by Warqaa Khalaf, Haithem Ahmed Al-Rubaie and Sami Shihab
Hematol. Rep. 2019, 11(1), 7708; https://doi.org/10.4081/hr.2019.7708 - 12 Mar 2019
Cited by 12 | Viewed by 883
Abstract
Anemia of chronic disease (ACD) and iron deficiency anemia (IDA) are the two most important types of anemia in rheumatoid arthritis (RA). Functional iron deficiency in ACD can be attributed to overexpression of the main iron regulatory hormone hepcidin leading to diversion of [...] Read more.
Anemia of chronic disease (ACD) and iron deficiency anemia (IDA) are the two most important types of anemia in rheumatoid arthritis (RA). Functional iron deficiency in ACD can be attributed to overexpression of the main iron regulatory hormone hepcidin leading to diversion of iron from the circulation into storage sites resulting in iron-restricted erythropoiesis. The aim is to investigate the role of circulating hepcidin and to uncover the frequency of IDA in RA. The study included 51 patients with RA. Complete blood counts, serum iron, total iron binding capacity, ferritin, and hepcidin- 25 were assessed. ACD was found in 37.3% of patients, IDA in 11.8%, and combined (ACD/IDA) in 17.6%. Serum hepcidin was higher in ACD than in control and the other groups (P ≤ 0.001). It was strongly and positively correlated with ferritin (P < 0.001), while hemoglobin, serum iron, and total iron binding capacity were negatively correlated with hepcidin (P = 0.016, 0.022 and <0.001, respectively). High serum hepcidin was significantly associated with ACD in RA. IDA alone or combined with ACD was encountered in about a third of patients. Full article
3 pages, 317 KiB  
Case Report
A Unique Case of Durable Complete Remission after Salvage with Azacitidine and DLI for High Risk FLT-3 Positive Acute Myeloid Leukemia, Following Relapse 18 Months Post Allogeneic Stem Cell Transplant
by Claire Horgan, Alexandros Kanellopoulos, Shankara Paneesha, Bhuvan Kishore, Richard Lovell and Emmanouil Nikolousis
Hematol. Rep. 2019, 11(1), 7800; https://doi.org/10.4081/hr.2019.7800 - 25 Feb 2019
Cited by 2 | Viewed by 399
Abstract
A unique case of primary refractory FLT3-itd mutated acute myeloid leukemia in an elderly patient, who achieved completed morphological remission, and FLT3-itd negativity, following 9 cycles of azacitadine in combination with escalating doses of donor lymphocyte infusions following relapse 18 months post reduced [...] Read more.
A unique case of primary refractory FLT3-itd mutated acute myeloid leukemia in an elderly patient, who achieved completed morphological remission, and FLT3-itd negativity, following 9 cycles of azacitadine in combination with escalating doses of donor lymphocyte infusions following relapse 18 months post reduced intensity HLAA mismatch Campath conditioning allogeneic stem cell transplant. Full article
2 pages, 284 KiB  
Case Report
Use of Catridecacog in a Patient with Severe Factor XIII Deficiency Undergoing Surgery
by Gianluca Sottilotta, Francesca Luise, Vincenzo Oriana, Angela Piromalli, Rosa Santacroce and Alessandra Di Lelio
Hematol. Rep. 2019, 11(1), 7912; https://doi.org/10.4081/hr.2019.7912 - 19 Feb 2019
Cited by 2 | Viewed by 409
Abstract
Despite many articles regarding the antihemorrhagic treatment and prophylaxis, there is a lack of experience about how to best conduct major surgical procedures in patients with congenital factor XIII (FXIII) deficiency. Here we report a case of surgery (right inguinal hernia, complicated by [...] Read more.
Despite many articles regarding the antihemorrhagic treatment and prophylaxis, there is a lack of experience about how to best conduct major surgical procedures in patients with congenital factor XIII (FXIII) deficiency. Here we report a case of surgery (right inguinal hernia, complicated by heaviness and pain) performed in a patient with FXIII deficiency, receiving recombinant FXIII prophylaxis (Catridecacog 35 UI/kg every 28 ± 2 days). Our experience shows that Catridecacog can be used safely and effectively not only for continued prophylaxis but also in surgery and adds to the very limited body of evidence currently available on surgery in this bleeding disorder. Full article
3 pages, 312 KiB  
Article
Patterns of Prescribing Hydroxyurea for Sickle Cell Disease Patients from a Central Hospital, Saudi Arabia
by Assem A. Elghazaly, Adel A. Aljatham, Abdulaziz M. Khan, Rasha M. Elneil, S. Zubair S. Jafar, Salah A. Elwishy, Omsalma E. Ahmed, Aamer M. Bughnah and Mamoun H. Ibrahim
Hematol. Rep. 2019, 11(1), 7860; https://doi.org/10.4081/hr.2019.7860 - 19 Feb 2019
Cited by 2 | Viewed by 459
Abstract
Sickle cell disease (SCD) is a group of inherited disorders of hemoglobin synthesis. It is prevalent in different parts of the world, including the Kingdom of Saudi Arabia. The disease is associated with multiple acute and chronic life-threatening complications. Hydroxyurea (HU) is an [...] Read more.
Sickle cell disease (SCD) is a group of inherited disorders of hemoglobin synthesis. It is prevalent in different parts of the world, including the Kingdom of Saudi Arabia. The disease is associated with multiple acute and chronic life-threatening complications. Hydroxyurea (HU) is an effective preventive medication; its use has resulted in decreased morbidity and mortality. However, practice variability, including underutilization of HU, has been reported. No local publication has addressed this issue. The aim of this work is to consider the pattern of HU prescription for SCD patients. This is a retrospective study included patients seen in the outpatient clinics in a central hospital. Cases of medications unavailability or patient refusal to take the drug were not included. A total of 152 patients were included, of them 118 were prescribed HU and 34 were not. In 133 (87.5%) patients, the physician’s decision was appropriate. Inappropriate decisions including both under prescription and, to much lesser extent, over utilization had been demonstrated in 19 (12.5%) cases. Impact of raising the healthcare providers’ awareness and improving compliance with the updated SCD management recommendations and guidelines deserve further studying. In our local experience, although the majority of HU prescriptions were appropriate, both under prescription and to a lesser extent, overutilization was demonstrated. Full article
3 pages, 441 KiB  
Case Report
Silent T-Cell Receptor Cutaneous T-Cell Lymphoma Associated to a Clonal Plasma Cell Proliferation
by Ana Caballero, Silvana Novelli, Anna Mozos, Pilar Garcia Muret, Jorge Sierra and Javier Briones
Hematol. Rep. 2019, 11(1), 7841; https://doi.org/10.4081/hr.2019.7841 - 19 Feb 2019
Cited by 5 | Viewed by 645
Abstract
Within T-cell lymphomas (TCL) there are 2 entities expressing gamma-delta TCR: hepatosplenic gamma-delta T-cell lymphoma (HSGDTL) and the primary cutaneous gamma-delta T-cell lymphoma (PCGDTL). PCGDTL is a rare form of T-cell lymphoma with specific tropism for skin that have a dismal prognosis. Although [...] Read more.
Within T-cell lymphomas (TCL) there are 2 entities expressing gamma-delta TCR: hepatosplenic gamma-delta T-cell lymphoma (HSGDTL) and the primary cutaneous gamma-delta T-cell lymphoma (PCGDTL). PCGDTL is a rare form of T-cell lymphoma with specific tropism for skin that have a dismal prognosis. Although even rarer, there have been reports of TCL with loss of expression of the TCR, which have been termed peripheral TCL TCR-silent type. We report the case of a cutaneous TCR-silent type lymphoma associated to a clonal plasma cell proliferation with an ominous outcome that led to a lot of discussion in its classification. Due to the aggressiveness of the disease and the scant evidence about therapy in this strange entity the outcome was fatal. We report a unique case of a TCR-silent cutaneous TCL with an exceptional histopathology, prolonged clinical evolution and a subsequent plasma cell clonal expansion. Full article
Previous Issue
Next Issue
Back to TopTop